It has been reported that BRAF inhibitors block the MAP kinase signaling pathway in BRAFV600E cells, whereas in BRAFWT tumors, BRAFi activates the RAF-MEK-ERK pathway and could enhance tumor growth in xenograft models [40, 41]. Here, MAPK1 is linked to neoplasm.